FindTrial
Sign In

Oxaliplatin Eugia 5 mg/ml concentraat voor oplossing voor infusie

DRUG3 trials

Sponsors

Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC), Catharina Ziekenhuis Stichting

Conditions

Patients with colorectal peritoneal metastases with a PCI-score of 1-20Resectable peritoneal metastases of a colorectal originlocally advanced rectal cancer

Phase 2

Neo-adjuvant intraperitoneal chemotherapy (irinotecan) and systemic chemotherapy (mFOLFOX4-bevacizumab) prior to CRS-HIPEC for patients with isolated resectable colorectal peritoneal metastases: a multicentre, phase II trial (INTERACT-PLUS)
Not yet recruitingCTIS2024-512318-16-00
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)Patients with colorectal peritoneal metastases with a PCI-score of 1-20
Target: 40Updated: 2026-01-02
Perioperative systemic therapy and cytoreductive surgery with HIPEC versus upfront cytoreductive surgery with HIPEC alone for resectable colorectal peritoneal metastases: a multicentre, open-label, parallel-group, phase II-III, randomised, superiority study (CAIRO6).
Not yet recruitingCTIS2024-518570-13-00
Catharina Ziekenhuis StichtingResectable peritoneal metastases of a colorectal origin
Target: 358Updated: 2024-11-13

Phase 3

Multicentre, open-label, randomised, controlled, parallel-arms, phase III, clinical trial of Neoadjuvant FOLFOXIRI and Chemoradiotherapy versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy, followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer: MEND-IT II
Not yet recruitingCTIS2025-523692-39-00
Catharina Ziekenhuis Stichtinglocally advanced rectal cancer
Target: 394Updated: 2026-02-04